MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2215/cjn.04760511

Медицинская библиотека · Clinical journal of the American Society of Nephrology : CJASN · 2012

Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial.

Shroff Rukshana, Wan Mandy, Gullett Ambrose, Ledermann Sarah, Shute Rachel, Knott Craig, Wells David, Aitkenhead Helen, Manickavasagar Bahee, van't Hoff William, Rees Lesley

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVES

Vitamin D deficiency is an important contributor to the development of hyperparathyroidism and is independently associated with cardiovascular and bone disease. The hypothesis was that nutritional vitamin D (ergocalciferol) supplementation in children with CKD stages 2-4 delays the onset of secondary hyperparathyroidism.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A randomized, double-blinded, placebo-controlled study in children with CKD2-4 who had 25-hydroxyvitamin D [25(OH)D] deficiency was conducted. Ergocalciferol (or a matched placebo) was given daily as per Kidney Disease Outcomes Quality Initiative guidelines. The primary endpoint was the time to development of hyperparathyroidism.

RESULTS

Seventy-two children were screened. Forty-seven children were 25(OH)D-deficient and randomly assigned to receive ergocalciferol or placebo. Twenty children in each arm completed the study; median follow-up was 12 months. Groups were well matched for age, race, estimated GFR, and season when recruited. Nine of 20 children on placebo and 3 of 20 children on ergocalciferol developed hyperparathyroidism (odds ratio, 4.64; 95% confidence interval, 1.02-21.00). The time to development of hyperparathyroidism was significantly longer with ergocalciferol treatment compared with placebo (hazard ratio, 0.30; 95% confidence interval, 0.09-0.93, P=0.05). With ergocalciferol treatment, normal 25(OH)D levels were achieved in all 8 children with CKD2, 8 of 11 children with CKD3, but not in the single patient with CKD4. There were no ergocalciferol-related adverse events. 25(OH)D levels >100 nmol/L were required to achieve normal levels of 1,25-dihydroxyvitamin D.

CONCLUSIONS

Ergocalciferol is an effective treatment that delays the development of secondary hyperparathyroidism in children with CKD2-3.

Для цитирования: Shroff Rukshana, Wan Mandy, Gullett Ambrose, Ledermann Sarah, Shute Rachel, Knott Craig, Wells David, Aitkenhead Helen, Manickavasagar Bahee, van't Hoff William, Rees Lesley. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial.. Clinical journal of the American Society of Nephrology : CJASN. 2012. DOI: 10.2215/cjn.04760511.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.